Clinical Trials for Medical Devices and Drugs Relating to COVID-19 Regulations, SOR/2022-18
Section 38
Exemption — positron-emitting radiopharmaceuticals
Cite as Clinical Trials for Medical Devices and Drugs Relating to COVID-19 Regulations, SOR/2022-18, s. 38 · current to July 24, 2025 · regulation last amended February 27, 2022
Statute Watch
Get an alert when a bill in Parliament would change this section, and every time it moves.
The text
(1) A person that is authorized under Division 3 of Part C of the Food and Drug Regulations to sell or import a positron-emitting radiopharmaceutical for the purposes of a study — and any other person that conducts the study — is, in respect of the study, exempt from section 3.1 of the Act.
(2) For greater certainty, the exemption does not apply
(a) if the authorization to sell or import the radiopharmaceutical is suspended in its entirety; or
(b) in respect of the conduct of the study at a study site, if the authorization to sell or import the radiopharmaceutical is suspended or cancelled in respect of that site.
Read the Clinical Trials for Medical Devices and Drugs Relating to COVID-19 Regulations on the Justice Laws Website ↗
Made under Food and Drugs Act, R.S.C. 1985, c. F-27; Patent Act, R.S.C. 1985, c. P-4.
Bills in Parliament that would change this section 0
No bill we hold would amend or repeal this section.